Most drug patent fights are decided before the courtroom ever opens.
In theory, the legal system rewards right. In practice, drug patent litigation is often won by the side that did the better work product first: better prior art searching, better clai…
The Prior Art Edge: Why Search Quality Beats Legal Firepower in Drug Patent Litigation Read Post »
Most drug patent fights are decided before the courtroom ever opens.
In theory, the legal system rewards right. In practice, drug patent litigation is often won by the side that did the better work product first: better prior art searching, better clai…
The Prior Art Edge: Why Search Quality Beats Legal Firepower in Drug Patent Litigation Read Post »
Pharma doesnt always need a better molecule to win. Sometimes it just needs a better schedule.
Heres the uncomfortable truth behind many patent cliffs: the battle isnt only over patentsits over timing, regulatory pathways, and commercial execution.
A r…
The Authorized Generic That Beats the Patent Cliff to Market Read Post »
Most portfolios dont have a patent problem. They have a timeline problem.
The gap between a truly defensible drug patent and the listed patent that appears in the regulatory record is often wider than investors realizeand its wide enough to turn upside…
One day. Nine figures. A lesson in what first really means.
The industry loves clean narratives: file first, win big, secure exclusivity. But the realityespecially in Hatch-Waxman and its modern cousinsis that patents are often won or lost in the margi…
One Day Late, Nine Figures Short: What Being the Second First-to-File Actually Costs Read Post »
One day late. Nine figures short.
Thats the headline lesson from a recent patent dispute in the pharmaceutical worldone where timing wasnt just important, it was existential. In a market built on years of R&D, regulatory timelines, and blockbuster …
One Day Late, Nine Figures Short: What Being the Second First-to-File Actually Costs Read Post »
The skinny label is often the earliest signal in the whole drug-patent cycle.
Most investors only start paying attention after the headline numbers appearcopycat approvals, label updates, or litigation thats already out in the open. But the real alph…
The Myth of the Stable Drug Patent Is Costing InvestorsAnd Patient AccessReal Time
In pharmaceuticals, everyone loves certainty.
Investors build models on it. Management teams defend pipelines with it. Lawyers structure deals around it. But the comfort…
The Myth of the Stable Drug Patent: Why IPRs Change the Game Overnight Read Post »
Drug Patent Watch argues that stable drug patents are a mythbecause in the real world, IPRs (Inter Partes Reviews) can flip the market overnight. Heres why that matters for investors, innovators, and anyone pricing risk in healthcare.
The story we tell…
The Myth of the Stable Drug Patent: Why IPRs Change the Game Overnight Read Post »
Patent strategy has become a game of choreographynot just litigation. And if youre still treating your Paragraph IV program like a one-time decision, youre already late to the rhythm.
The latest insight from DrugPatentWatchPredictable by Design: How Br…
Predictable by Design: How Brands Outmaneuver Your Paragraph IV Strategy Read Post »
Get new actionable insights and updates from BiotechBlog
